Some key points from the article are listed below. But full explanations and cautions are in the article. This data is from the UK Health Security Agency (UKHSA

Some key points from the article are listed below. But full explanations and cautions are in the article. This data is from the UK Health Security Agency (UKHSA). --- Protection against death (mortality) Vaccine effectiveness against death (mortality) from Omicron in those aged over 50 (it is too early to produce accurate data for those aged under 50): - After two doses: 59% after twenty-five weeks - After a booster dose: 95% after two weeks --- Protection against severe disease requiring hospitalisation from Omicron - After two doses of any vaccine: 25-35% protection after twenty-five weeks - After a Pfizer booster: around 90%, dropping to around 75% after ten to fourteen weeks - After a Moderna booster: 90-95% up to nine weeks after vaccination Hospitalisations prevented: Latest analysis estimates the boosters alone prevented 105,600 hospitalisations in those aged 25 and over in England between December 13 2021 and February 6 2022. --- Protection against symptomatic disease (mild infection) - After two doses of AstraZeneca: around 50% protection, waning to almost 0% from twenty weeks - After two doses of Pfizer or Moderna: 65-75% protection, waning to around 10% by twenty-five weeks after the second dose - After a booster dose: 65-75% protection after two to four weeks, waning to 30-40% after fifteen weeks --- Protection against infection (including asymptomatic infection) Vaccine effectiveness against infection from Delta (including asymptomatic infection): - After two doses of AstraZeneca: Estimated at around 50% after two months - After two doses of Pfizer: Estimated at around 81% after two months, waning to around 46% after six months --- Prevention of transmission Effectiveness of the vaccines against transmission of the Delta variant: - After two doses of AstraZeneca: Estimated at 42% - After two doses of Pfizer: Estimated at 31% --- Additional vaccine protection for those with prior infection (infection-derived immunity) Early evidence shows that getting vaccinated after infection provides significantly higher levels of protection against reinfection. Protection against reinfection from Omicron: - No vaccination and prior infection: Estimated at 44% - Prior infection and three vaccine doses: Estimated at 71%